Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 14, 2012Mon, February 13, 2012Sun, February 12, 2012Fri, February 10, 2012Thu, February 9, 2012Wed, February 8, 2012Tue, February 7, 2012Mon, February 6, 2012Sun, February 5, 2012Sat, February 4, 2012Fri, February 3, 2012Thu, February 2, 2012Wed, February 1, 2012MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Published in Health and Fitness on Wednesday, February 8th 2012 at 4:16 GMT by Market Wire
MAP Pharmaceuticals to Present at Upcoming Investor Conferences -- id='temp_ReleaseStart'>MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ --
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: [ MAPP ]) today announced that the Company will participate in the following investor conferences in February 2012:
Leerink Swann 2012 Global Healthcare Conference
Thursday, February 16, at 11:30 a.m. ET in New York
2012 Citi Global Healthcare Conference
Tuesday, February 28, at 8:00 a.m. ET in New York
A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at [ http://www.mappharma.com ]. A replay also will be available within 24 hours for seven days following each presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at [ http://www.mappharma.com ].
CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
[ lborland@mappharma.com ]
SOURCE MAP Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.mappharma.com ]
